Soft Tissue Sarcoma Type: Key Facts to Understand
====================================================================
Synovial sarcoma is a rare and aggressive subtype of soft tissue sarcoma, accounting for a small percentage of these cancers. This type of cancer originates from soft connective tissues and can develop in various parts of the body, including arms, legs, feet, near joints like ankles or wrists, lungs, abdomen, and bones.
Anyone experiencing unexplained pain, swelling, and lumps in the body, particularly in these areas, should consult a doctor. It is essential to note that synovial sarcoma is not hereditary.
The main symptoms of synovial sarcoma include pain, reduced range of motion in an affected joint, swelling, and numbness. Doctors may use MRI scans to diagnose synovial sarcoma and biopsies to differentiate it from other soft tissue sarcomas.
If a doctor diagnoses synovial sarcoma early, there is more chance of treating it before it has metastasized. Synovial sarcomas develop slowly, often causing symptoms for 2 years before diagnosis.
Effective management of synovial sarcoma often requires a multidisciplinary team approach, involving surgical oncologists, medical oncologists, radiation oncologists, and supportive care specialists to optimize treatment outcomes.
Treatment Options
The first and primary form of treatment for synovial sarcoma is surgery, aiming to remove as much of the tumor as possible. In some cases, the affected limb or surrounding tissue may need to be removed.
Chemotherapy is often used in combination with surgery to treat synovial sarcoma. It can be given before or after surgery to help control the tumor size and reduce the risk of recurrence.
Adjuvant radiotherapy is commonly used after surgery to kill any remaining cancer cells, especially in cases where the tumor is large or in difficult locations. Advanced techniques like intensity-modulated radiotherapy (IMRT) are preferred for better local tumor control and to minimize side effects.
Immunotherapy, particularly T-cell therapies targeting specific cancer antigens like NY-ESO-1, is being explored for synovial sarcoma. A recent example is the use of afamitresgene autoleucel (afami-cel), which has shown promising results in clinical trials.
Targeting the epigenetic machinery associated with the SS18::SSX fusion protein is a promising therapeutic strategy for synovial sarcoma. However, more research is needed to develop effective targeted therapies.
In some cases, chemotherapy may be appropriate, involving the injection of chemicals into the bloodstream to kill cancer cells. Chemotherapy is useful when surgeons cannot remove every tumor or if cancer has spread to other body parts.
Support and Information
The cause of synovial sarcoma is not fully understood, but factors such as genetic mutations, exposure to radiation, and exposure to carcinogens may contribute. Avoiding exposure to radiation and carcinogens may lower the risk of developing this condition, but there is no way to prevent synovial sarcoma with any certainty.
Certain charities and associations, such as The Cancer Support Center and Cancer Research UK, can provide information and support to those living with synovial sarcoma. It is crucial for those with concerns to speak with a doctor about their symptoms and potential treatment options.
According to the NCI, between 50-60% of people with synovial sarcoma survive for at least 5 years after their diagnosis. The lungs are the most common location for synovial sarcoma metastases. Doctors may also recommend radiation therapy, either before or after surgery, to kill cancer cells.
Science and medical research continue to advance our understanding of other cancers, including synovial sarcoma. In the realm of health and wellness, it's important to recognize that exposure to carcinogens and radiation may increase the risk of developing certain medical conditions, such as synovial sarcoma. Consulting knowledgeable sources, like The Cancer Support Center and Cancer Research UK, can provide valuable information and support in managing this disease. Additionally, staying informed about innovative treatment options, such as immunotherapy and targeted therapies, can help patients make informed decisions about their health.
